Pujol M, Muñoz M, Prat J, Girona V, De Bolós J
Departament de Farmàcia, Facultat de Farmàcia, Universitat de Barcelona, Spain.
Ann Pharmacother. 1997 Sep;31(9):992-5. doi: 10.1177/106002809703100906.
To determine the stability of epirubicin in NaCl 0.9% injection under hospital storage conditions.
NaCl 0.9% solution was added to epirubicin lyophilized powder to make a final concentration of 1 mg/mL to study the degradation kinetics and 2 mg/mL to study the stability in polypropylene syringes under hospital conditions.
Physical chemistry laboratory, Unitat de Fisicoquímica, Universitat de Barcelona.
Solutions of epirubicin at 2 mg/mL in NaCl 0.9% solutions stored in plastic syringes were studied under hospital conditions at room temperature (25 +/- 1 degrees C) and under refrigeration (4 +/- 1 degrees C) both protected from light and exposed to room light (approximately 50 lumens/m2). All samples were studied in triplicate and epirubicin concentrations were obtained periodically throughout each storage/time condition via a specific stability-indicating HPLC method. To determine the degradation kinetics, solutions of epirubicin in NaCl 0.9% at 1 mg/mL were stored at different temperatures (40, 50, and 60 degrees C) to obtain the rate degradation constant and the shelf life at room temperature and under refrigeration.
The degradation of epirubicin in NaCl 0.9% solutions follows first-order kinetics. The shelf life was defined as the time by which the epirubicin concentration had decreased by 10% from the initial concentration. In this study, epirubicin was stable in NaCl 0.9% injection stored in polypropylene containers for all time periods and all conditions. That results in a shelf life of at least 14 and 180 days at 25 and 4 degrees C, respectively. The maximum decrease in epirubicin concentration observed at 25 degrees C and 14 days was 4%, and at 4 degrees C and 180 days was 8%. The predicted shelf life obtained from the Arrhenius equation was 72.9 +/- 0.2 and 3070 +/- 15 days at 25 and 4 degrees C, respectively, in both dark and illuminated conditions.
Solutions of epirubicin in NaCl 0.9% at 2 mg/mL are chemically stable when they are stored in polypropylene syringes under hospital storage conditions. No special precaution is necessary to protect epirubicin solutions (2 mg/mL) from light.
确定表柔比星在医院储存条件下于0.9%氯化钠注射液中的稳定性。
将0.9%氯化钠溶液加入表柔比星冻干粉末中,使其终浓度为1mg/mL以研究降解动力学,终浓度为2mg/mL以研究在医院条件下于聚丙烯注射器中的稳定性。
巴塞罗那大学物理化学单元物理化学实验室。
研究在医院条件下,室温(25±1℃)和冷藏(4±1℃)、避光和暴露于室内光(约50流明/平方米)条件下,储存在塑料注射器中的0.9%氯化钠溶液中浓度为2mg/mL的表柔比星溶液。所有样品均重复研究三次,并通过特定的稳定性指示高效液相色谱法在每个储存/时间条件下定期获取表柔比星浓度。为确定降解动力学,将1mg/mL的表柔比星在0.9%氯化钠溶液中的溶液储存在不同温度(40、50和60℃)下,以获得降解速率常数以及在室温和冷藏条件下的保质期。
表柔比星在0.9%氯化钠溶液中的降解遵循一级动力学。保质期定义为表柔比星浓度从初始浓度下降10%所需的时间。在本研究中,表柔比星在所有时间段和所有条件下储存在聚丙烯容器中的0.9%氯化钠注射液中均稳定。这导致在25℃和4℃下的保质期分别至少为14天和180天。在25℃和14天时观察到的表柔比星浓度最大降幅为4%,在4℃和180天时为8%。根据阿累尼乌斯方程预测,在25℃和4℃下,无论在黑暗还是光照条件下,保质期分别为72.9±0.2天和3070±15天。
当浓度为2mg/mL的表柔比星在0.9%氯化钠溶液中储存在医院储存条件下的聚丙烯注射器中时,化学性质稳定。无需采取特殊预防措施来保护表柔比星溶液(2mg/mL)免受光照。